✦ LIBER ✦

Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism

✍ Scribed by Cédric Mercier; Laetitia Dahan; L’Houcine Ouafik; Nicolas André; Joseph Ciccolini

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of gemcitabine in non-s

✍ Jan Gerard Maring; Floris M. Wachters; Monique Slijfer; J. Marina Maurer; H. Mar 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 152 KB

Pharmacology of the paclitaxel–cisplatin

✍ J. R. Kroep; E. F. Smit; G. Giaccone; K. Van der Born; J. H. Beijnen; C. J. Van 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 248 KB

Impact of functionalABCG2polymorphisms o

✍ Keiichi Akasaka; Takayuki Kaburagi; Shin’ichi Yasuda; Kyoko Ohmori; Kaori Abe; H 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 212 KB

A pilot study on safety and pharmacokine

✍ Aminah Jatoi; James R. Jett; Jeff Sloan; Paul Novotny; Joyce Ford; Uma Prabhakar 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 162 KB

Docetaxel/gemcitabine or cisplatin/gemci

✍ D. Binder; H. Schweisfurth; C. Grah; C. Schäper; B. Temmesfeld-Wollbrück; G. Sie 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 340 KB

The effect of bexarotene on atorvastatin

✍ Heather A. Wakelee; Chris H. Takimoto; Arturo Lopez-Anaya; Quincy Chu; Gary Midd 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 393 KB